Exelixis Hopes CABOSUN Means New Dawn For Cabometyx In Frontline Kidney Cancer
Exelixis’s plan to file an sNDA, based on positive results in the Phase II CABOSUN study, could support an early approval for cabozantinib in first-line kidney cancer, spuring more change in the crowded kidney cancer market
You may also be interested in...
Keeping Track: Oncology Stays Hot With Besponsa And Lynparza Approvals; New Uses Of Adcetris, Cabometyx Submitted
The latest drug development news and highlights from our US FDA Performance Tracker.
Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.
A NICE knock-back for Ipsen's Cabometyx in renal cell carcinoma (RCC) means less pressure on BMS's embattled Opdivo, but not for long if Ipsen is willing to compromise on price, warn analysts.